Clinical Trials Logo

Schizoaffective Disorder clinical trials

View clinical trials related to Schizoaffective Disorder.

Filter by:

NCT ID: NCT00018642 Completed - Schizophrenia Clinical Trials

Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder

Start date: April 1997
Phase: N/A
Study type: Interventional

The purpose of this research study is to determine whether a new drug for schizophrenia is better for the maintenance treatment than a standard drugs currently prescribed. The new medication is called quetiapine and it will be compared with a standard medication called haloperidol decanoate. The study will determine if quetiapine causes fewer problems than haloperidol with side effects such as stiffness and restlessness and whether it costs the VA more or less to treat patients with quetiapine. In addition, blood samples will be collected every three months to determine if certain chemicals in the blood can influence the outcome of the subjects' illness.

NCT ID: NCT00018629 Completed - Schizophrenia Clinical Trials

Cognitive - Behavioral Therapy

Start date: May 2000
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if Cognitive - Behavioral Social Skills Training (CBSST) improves functioning in older patients with schizophrenia.

NCT ID: NCT00007774 Completed - Schizophrenia Clinical Trials

To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia

Start date: March 1998
Phase: Phase 4
Study type: Interventional

Although currently marketed antipsychotic drugs are useful in the treatment of schizophrenia, efficacy and safety profiles need to be improved. Forty to eighty percent of patients either fail to respond or only partially respond to conventional antipsychotic agents. Secondary symptoms may be unimproved even in patients who respond to treatment. A variety of adverse events occur in patients receiving currently available agents. The severity of these events contributes to the poor compliance that is observed in this patient population. Olanzapine is a novel antipsychotic agent with a reduced incidence of extrapyramidal symptoms. Other side effects are minimal.